Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
READ BETWEEN THESE LINES! Here are some quotes (not many) from the past year plus of Q's and K's regarding "BUSINESS DEVELOPMENT". If I include PR's and emails received regarding this term you can really piece together when IPIX began rolling up their sleeves and negotiating with BP. I feel good where we are at and am excited for the first partnership:
9/8/17 10-K --- **** No Business Development Terms ****
11/8/17 10-Q pg28
The Company expects to seek to obtain additional funding through business development activities (i.e. licensing and partnerships) and future equity issuances. There can be no assurance as to the availability or terms upon which such financing and capital might be available to us.
A key strategic priority for the Company remains the out-licensing of its mid-stage, first-in-class clinical assets to global and/or specialty pharmaceutical companies who have expressed an interest in our pipeline. Successfully securing partnerships would afford the Company access to immediate and potentially recurring sources of non-dilutive capital, including upfront fees, milestone-based payments and tiered royalties.
The Company devotes most of its efforts and resources on business development and the clinical trials of its compounds.
The Company is engaged in discussions and negotiations regarding the out-licensing of its mid-stage, first-in-class clinical assets to global and/or specialty pharmaceutical companies who have expressed an interest in one or more assets in our pipeline. Successfully securing partnerships would afford the Company access to immediate and potentially recurring sources of non-dilutive capital, including upfront fees, milestone-based payments and tiered royalties.
Recently, we released results from our completed Phase 2 Brilacidin study on Oral Mucositis. The results have attracted inquiries, additional confidential disclosure agreements, and discussions with pharmaceutical companies.
pg29 We are actively engaged in licensing discussions with global pharmaceutical companies. Successfully securing partnerships would afford the Company access to immediate and potentially recurring sources of non-dilutive capital, including upfront fees, milestone-based payments and tiered royalties. There can be no assurance that the Company will be successful in these business development activities.
pg 5
In the ordinary course of business, we engage in a continual review of opportunities to license our drug compounds and enter into partnering, joint development or similar arrangements with other companies. We currently, and generally at any time, have such opportunities in various stages of active review, including, for example, entry into indications of interest and term sheets and participation in preliminary discussions and negotiations. Any such transaction could be material to us.
pg43
The Company signed a non-binding term sheet in August 2018 with a global pharmaceutical company for the licensing/rights to Brilacidin for treating oral mucositis and inflammatory bowel diseases. Initial payments, milestone payments and royalties are being negotiated in accordance with the non-binding term sheet. The pharmaceutical company is now engaged in further due diligence. Management can offer no assurances that the parties will enter into a binding definitive agreement.
The Company is actively engaged in business development and licensing initiatives with multiple specialty and global pharmaceutical companies across its entire pipeline of drugs. From time to time, the Company may be party to various indications of interest and term sheets and participate in preliminary discussions and negotiations regarding potential licensing or partnership arrangements. It remains the Company’s primary objective to complete licensing deals, territorial and/or global, to provide access to non-dilutive capital to advance clinical assets forward in the most expeditious and cost-effective manner. The Company can make no assurance that partnerships will occur, but is committed toward executing on these potential alliance and partnership opportunities.
While utilizing all available tools to defend the Company and its assets against fake news, there is limited regulatory control, making fake news an ongoing concern for any public company. While we move forward in our business development strategies in good faith, there are no assurances that we will not face more fake news or similar tactics by bad actors in the future, and the market price of our common stock may decline as a result of their actions or the action of other short sellers.
The lease included an automatic renewal provision for a term of five years from September 30, 2018 to September 30, 2023, and requires monthly payments of approximately $19,000. The total square footage of the space is substantially more than what is currently needed for our operations; the majority of the space is a laboratory. The Company believes, however, that if we are successful with advancing our Brilacidin Oral Mucositis and/or Prurisol Psoriasis programs into confirmatory studies, we will need all, or most of, the space as we could save substantial monies by doing in house functions that would otherwise be outsourced to contract research organizations. In the interim, we are planning to sublet laboratory space as we are now focused on conducting clinical studies.
Where does it say that?
In the K it said we owed approx 4 million to CRO now it says 3 million. So we paid 1 million? Plus we paid 1 million to B manufacturer. That is my guess.
163,676,190. As of Nov 2nd. August 27th was 161,103,927. Interesting. To me
So all the selling? Where is it from? OS increased by LESS than 500k since August.
163k outstanding AGAIN? Hmmmmmmmmm
U back in...?
I’m confident ipix will deliver a partnership. That’s why I buy. In my investing career these are the stocks you make life changing money. It helps it’s bio too, because one day you sit at .15 the next you open at 2.30. IBD and an untapped OM is worth a ton of money. OM = swish and spit = priceless. The numbers where phenomenal for highest dose of cisplatin.
Not really. With 20-100 million upfront, anything can happen. Not too many shares have been sold in the .12-.40 range. 20 million maybe?
Remember only 45 million new shares have entered since $4.40
That is not a lot in this world. Bios with ONE drug that makes it to blockbuster status have MCs in the several of billions. We have 3 shots on goal for blockbusters. Maybe more with multiple indications of B
Do you read? A BP required two items for partnership. 1). Observe p53 inter-tumor modulation.
2). Develop Oral
#1 was the ovarian trial. It was a success and cut short because we did not have to waste more money. We observed what we needed and moved on to Oral. That is where we are now.
All trials have been successful -
Right. And there was so much more risk....compared to today. 45 million shares to complete 5 trials and fund the business for 3.5 years is ABSOLUTELY not worth the SP decline. Just saying. This will kick it into gear overnight. Ipix will close this deal and overnight this goes over highs
$4.40 a share - Dec 31st 2014: Comparing to 2012 which should show just how undervalued we are with zero FAILURES in the clinic, here are some facts from when we were at the HIGH of IPIX:
Dec 31st 2014 - Share price - $4.40
Cash on hand - 9.4 million
Total OS - 117 Million (ish)
PROGRESS
1) Kevetrin - In Progress Phase 1 - Enrolling in the 10th cohort
2) Prurisol - Successful Phase 1 Completed - Comparing bio-availability b/w P and Ziagen
3) B-Absssi - Successful Phase 2b Completed - Topline data Oct 23rd - full data in 2015 to be announced
4) B-OM - IND filed in Sept 2014 and granted by FDA in Oct 2014
**2 Successful Human Trials to date**
https://www.bamsec.com/filing/147793215001033?cik=1355250
Posted in Feb2015 for Q ending Dec 31st 2014
August 27th 2018 - .40
Cash on hand - 2.4 million
Total OS - 163 Million
PROGRESS
1) Kevetrin - Phase 1 Successful (Solid Tumors)
2) Kevetrin - Phase 2 Successful (Ovarian)
3) Prurisol - Phase 2a Successful (Mild - Moderate Psoriasis)
4) Prurisol - Phase 2b Completed (Moderate - Severe Psoriasis) AWAITING DATE
5) B-OM - Phase 2 Successful (Oral Mucositis - PREVENTION) Leader in an untapped market
6) B-UP/UC - Phase 2 PoC Successful
**5 Additional late stage Human trials SUCCESSFUL - Awaiting data on a Phase 2b for Prurisol**
So to summarize - in 3.5 years IPIX was able to complete 5 SUCCESSFUL human trials and awaiting on data for a phase 2b.
The share count increased by about 45 Million shares.
NR and a whole bunch of peeps that bought in at .12-.13. Remember we had a nice 40% plus increase on Friday. NR said he made 5K and sold today. Next move up tomorrow. .185 to 27 cents tomorrow. Let’s roll maxxypaddd
It was just NR exiting .... back up we go. And less baggage.
On this Skype chat I’m a part of. Crazy stuff.
I hear a pump is coming. Prob same bastards that took it down here...or for the other boogeyman stories maybe the BP has finalized the deal for the much cheaper price (mission accomplished). and now that it will be finalized public soon it shall now make those rich that took it down. Whatever! I’ll take whatever pump and hopefully the deal is finalized to keep it going for real.
All the rumorbuzz tweets, now this article, I also have seen some big time board peeps talking about ipix on private boards.
I just want Kevetrin to help cancer patients. And the other drugs as well.
Roll Tide
Thanks. LR. You are valuable in some instances. ;)
Pisses me off we are happy about 5 cents, I’ll take it obviously, but this should be moving dollars at this stage. IMO. TGIF!!!!
Cheers to ipix getting back to where it should be!
Agree. We have a few good weeks ahead with presentations and Q’s and possible BTD.
Let’s step back and take out the noise: Leo wanted to reiterate the trial data that they will focus on. Now a smart investor can see those and compare to all others in trials and see BOM for this specific patient set is the clear leader. Nothing is guaranteed.
However our chances are very good.
Earnings per year will be in the 200-400 million to start imo. Our market cap is 20. Lol.
I bought 77k at the ask each time....because this price is dumb.
Rehash; Poly was purchased on BK for just over 5 million plus. Our market cap is 22million. I mean we took B-Absssi through phase 2b with menons tweaks and compared to Dapto. We started B-OM and got through phase 2 waiting on meeting with fda for phase 3z. We started Phase 2 with uc/Up and crushed it with photos!!! All of that plus more pre clinical and we sit at a 22mil market cap. Come on. This is a 200-300 mil mc at lowest until financing becomes available. IMO.
Today’s news is good. Patent rights are gold and I’m sure BP is doing their DD on these types of things. Maybe this is all happening because it’s required...?
One day closer to Dday
In one day —- this stock soars back into dollar range and the aspire agreement is still in fact a go. If ipix cancel current one the aspire is back on as long as above 25 cents. Still have 22 million there
Come on RDunn. We will see in 10 days what the OS is. I bet it’s at 175ish tops.
Absssi sitting at phase 3. Comparable to a billion dollar drug.
BOM. BLUE sky market. No competition in billion market Plus prevention —- going into phase 3
IBD. Multiple indications....several billion if formulation works. Big if.
Prurisol could be multiple billions a year. Waiting on data for phase 2b
Kevetrin could be the best drug in this world if Oral pans out. 5+ billion a year especially for prevention.
Others.....
I do t know what you get at this phase but every billion is just over 4 dollars
About how long it takes. You want me to post a filing detailing 4 years of negotiations for a recent deal? 3-4 separate BPs over 4 years of negotiations. To finally ink. It’s going to happen. And I believe in the next few weeks. Pfizer tresses q3 this am. Will be listening for clues
Lol. Soon this crap will stop and we can concentrate on possible values of ipix drugs. 20 CDAs were not a joke or fluff. 20 real BPs and Bios are interested. Close a deal with the best partner and we take off to true valuations. Can’t wait. ;)
Soon: you will have zero ammunition. Soon it will be only about the science that has never failed. Soon you will have no legs to stand on here. Money will be no worry. Leo will have proven everything he has been working for...and it will be all about the science. All of a sudden very good P results become very valuable and worth exactly what they should be. Everything changes here....SOON!
Nope. Not sure about the connection. I was under the impression that Pfizer was the Kevetrin play years ago. So if that rumor tweet about Pfizer for OM and IBD....it will be interesting to see. Maybe they want to be our sole partner for buyout in the years to come but want IPIX to continue and show what they ask for until basically all RISK is taken out.
Great times ahead - just need to get by this dilution and it looks slower than initial first weeks. Imo
I heard these results may be coming soon...looking for 30-50% pasi 75. If so, game over for the other side
They have all info in every big BP already. We all would be surprised by how many meetings ipix has had. This Term Sheet BP is over 2 years in the making. Ipix has done its DD and this is the one. Just waiting for ink to dry. I’m 99.9% this is the one. Big money about to be infused in ipix. Everything we have been waiting for imo. Hold tight imo. Very very soon.
Same with Jazz. Never saw a freak out like it. People screaming bankruptcy etc....from $13 to .50......what’s JaZZ at now?
I meant milestones. Ha! IBD is gonna be big...real big
I’m talking about NEWS! The news we will eventually get of 100 million upfront, 656 million in royalties...etc...
Or P data of 37% pasi 75
Now that is news to put this over all time highs.
Remember boy. Only 40 plus million added to OS since were at 4.70. There is severe disconnect.
I mean Buckle Up! I don’t think there is a belt that can save us from where are now to where we are headed....
It will be fun when they drop the news........imo.
Did we decide whether announcing a TERM SHEET in the 10K was a material event? Of if it was cancelled it would have to be 8K'd?
I’ve seen 3. Sub penny to over 20 dollars was the best I’ve seen.
Multi Family Office bruha
At some point when MFO is full they will want this to run. News or no news. IMO. They are not here for friends.
Another Green Day! 2 in a row!